What is a stock summary page? Click here for an overview.
Business Description
Aligos Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US01626L1052
Share Class Description:
ALGS: Ordinary SharesDescription
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.8 | |||||
| Equity-to-Asset | -0.41 | |||||
| Debt-to-Equity | -0.29 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -17.42 | |||||
| Beneish M-Score | -3.57 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -38.7 | |||||
| 3-Year EBITDA Growth Rate | 43.9 | |||||
| 3-Year EPS without NRI Growth Rate | 42.7 | |||||
| 3-Year FCF Growth Rate | 43.9 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.86 | |||||
| 9-Day RSI | 27.28 | |||||
| 14-Day RSI | 28.82 | |||||
| 3-1 Month Momentum % | -59 | |||||
| 6-1 Month Momentum % | 109.83 | |||||
| 12-1 Month Momentum % | -31.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.86 | |||||
| Quick Ratio | 2.86 | |||||
| Cash Ratio | 2.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -31.3 | |||||
| Shareholder Yield % | 4.24 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2259.92 | |||||
| Net Margin % | -3326.01 | |||||
| FCF Margin % | -2050.01 | |||||
| ROE % | -273.1 | |||||
| ROA % | -119.99 | |||||
| ROIC % | -490.61 | |||||
| 3-Year ROIIC % | -129.64 | |||||
| ROC (Joel Greenblatt) % | -1038.22 | |||||
| ROCE % | -101.84 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 14.5 | |||||
| EV-to-EBIT | -0.08 | |||||
| EV-to-EBITDA | -0.08 | |||||
| EV-to-Revenue | 1.82 | |||||
| EV-to-Forward-Revenue | 0.1 | |||||
| EV-to-FCF | -0.09 | |||||
| Price-to-GF-Value | 4.24 | |||||
| Earnings Yield (Greenblatt) % | -1250 | |||||
| FCF Yield % | -145.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ALGS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aligos Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.945 | ||
| EPS (TTM) ($) | -20.9 | ||
| Beta | 2.36 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.37 | ||
| Volatility % | 200.95 | ||
| 14-Day RSI | 28.82 | ||
| 14-Day ATR ($) | 1.569434 | ||
| 20-Day SMA ($) | 11.519 | ||
| 12-1 Month Momentum % | -31.14 | ||
| 52-Week Range ($) | 6.76 - 46.8 | ||
| Shares Outstanding (Mil) | 6.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aligos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aligos Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aligos Therapeutics Inc Frequently Asked Questions
What is Aligos Therapeutics Inc(ALGS)'s stock price today?
The current price of ALGS is $9.12. The 52 week high of ALGS is $46.80 and 52 week low is $6.76.
When is next earnings date of Aligos Therapeutics Inc(ALGS)?
The next earnings date of Aligos Therapeutics Inc(ALGS) is 2025-05-07 Est..
Does Aligos Therapeutics Inc(ALGS) pay dividends? If so, how much?
Aligos Therapeutics Inc(ALGS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers